Comparative diagnostic study of biomarkers using FibroMax™ and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study
Authors Fouad A, Sabry D, Ahmed R, Kamal M, Abd Allah S, Marzouk S, Amin M, Abd El Aziz R, El Badri A, Khattab H, Helmy D
Received 27 July 2012
Accepted for publication 1 November 2012
Published 12 March 2013 Volume 2013:6 Pages 127—134
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Ahmad Fouad,1,* Dina Sabry,2 Rasha Ahmed,1,* Manal Kamal,3,* Sayed Abd Allah,4,* Samar Marzouk,2,* Mona Amin,4,* Rokaya Abd El Aziz,4* Ahmad El Badri,4 Hany Khattab,5,* Dina Helmy,5,*
1Endemic Medicine Department, 2Medical Biochemistry and Molecular Biology Department, 3Clinical and Chemical Pathology Department, 4Internal Medicine Department, 5Pathology Department, Faculty of Medicine, Cairo University, Egypt
*These authors contributed equally to this work
Background: Steatosis is common in patients with hepatitis C virus (HCV) infection and may be a major determinant of progression of liver injury. This study evaluated FibroMax™ for noninvasive diagnosis of steatosis in patients with chronic HCV.
Methods: This cross-sectional study included 44 patients naïve to treatment who were referred to our hepatology clinic for assessment of fitness for antiviral therapy. Chronic HCV infection was diagnosed by viral markers. Investigations included assessment of abdominal ultrasonography, liver biopsy, calculation of body mass index, and biomarker parameters in serum using FibroMax.
Results: Histopathology of liver biopsies showed steatosis in 30 of 44 (68%) patients. FibroMax results were positively correlated with viral load by quantitative polymerase chain reaction and histopathological findings. Body mass index was significantly higher in steatotic patients (P = 0.003) and was significantly associated with the results on FibroMax (P = 0.005).
Conclusion: FibroMax was correlated with histopathology and body mass index in patients with HCV. Abdominal ultrasonography could not be used as a single tool to diagnose steatosis with HCV. Steatosis is correlated with viral load, which suggests a direct viral effect. We recommend FibroMax assessment in a larger number of patients to assess its applicability in patients with HCV and steatosis.
Keywords: steatosis, hepatitis C virus, histopathology, FibroMax™
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]